Logo image of CTKB

CYTEK BIOSCIENCES INC (CTKB) Stock Fundamental Analysis

NASDAQ:CTKB - Nasdaq - US23285D1090 - Common Stock - Currency: USD

5.12  -0.08 (-1.54%)

After market: 5.12 0 (0%)

Fundamental Rating

4

Overall CTKB gets a fundamental rating of 4 out of 10. We evaluated CTKB against 56 industry peers in the Life Sciences Tools & Services industry. CTKB has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CTKB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CTKB has reported negative net income.
CTKB had a positive operating cash flow in the past year.
In multiple years CTKB reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CTKB reported negative operating cash flow in multiple years.
CTKB Yearly Net Income VS EBIT VS OCF VS FCFCTKB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

CTKB has a Return On Assets of -3.63%. This is in the better half of the industry: CTKB outperforms 64.91% of its industry peers.
With a decent Return On Equity value of -4.51%, CTKB is doing good in the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
ROA -3.63%
ROE -4.51%
ROIC N/A
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A
CTKB Yearly ROA, ROE, ROICCTKB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10 -20 -30 -40 -50

1.3 Margins

CTKB has a Gross Margin of 54.97%. This is in the better half of the industry: CTKB outperforms 71.93% of its industry peers.
CTKB's Gross Margin has been stable in the last couple of years.
CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A
CTKB Yearly Profit, Operating, Gross MarginsCTKB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTKB has less shares outstanding
Compared to 1 year ago, CTKB has an improved debt to assets ratio.
CTKB Yearly Shares OutstandingCTKB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CTKB Yearly Total Debt VS Total AssetsCTKB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 5.11 indicates that CTKB is not in any danger for bankruptcy at the moment.
CTKB has a better Altman-Z score (5.11) than 78.95% of its industry peers.
The Debt to FCF ratio of CTKB is 0.31, which is an excellent value as it means it would take CTKB, only 0.31 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.31, CTKB belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CTKB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CTKB is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.31
Altman-Z 5.11
ROIC/WACCN/A
WACC11.31%
CTKB Yearly LT Debt VS Equity VS FCFCTKB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

CTKB has a Current Ratio of 7.33. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB has a Current ratio of 7.33. This is amongst the best in the industry. CTKB outperforms 82.46% of its industry peers.
A Quick Ratio of 6.38 indicates that CTKB has no problem at all paying its short term obligations.
CTKB's Quick ratio of 6.38 is amongst the best of the industry. CTKB outperforms 82.46% of its industry peers.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 6.38
CTKB Yearly Current Assets VS Current LiabilitesCTKB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CTKB have decreased strongly by -215.94% in the last year.
CTKB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.88%.
The Revenue has been growing by 27.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1100%
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%7.29%

3.2 Future

The Earnings Per Share is expected to decrease by -10.88% on average over the next years. This is quite bad
CTKB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.65% yearly.
EPS Next Y-241.55%
EPS Next 2Y-42.89%
EPS Next 3Y-10.88%
EPS Next 5YN/A
Revenue Next Year6.31%
Revenue Next 2Y7.25%
Revenue Next 3Y8.65%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTKB Yearly Revenue VS EstimatesCTKB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
CTKB Yearly EPS VS EstimatesCTKB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 0 0.05 -0.05 0.1 -0.1 0.15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTKB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CTKB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTKB Price Earnings VS Forward Price EarningsCTKB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CTKB indicates a somewhat cheap valuation: CTKB is cheaper than 63.16% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 61.91
EV/EBITDA N/A
CTKB Per share dataCTKB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as CTKB's earnings are expected to decrease with -10.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.89%
EPS Next 3Y-10.88%

More info and screens

0

5. Dividend

5.1 Amount

CTKB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (2/21/2025, 8:11:14 PM)

After market: 5.12 0 (0%)

5.12

-0.08 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners60.89%
Inst Owner Change-92.1%
Ins Owners8.85%
Ins Owner Change0.57%
Market Cap659.51M
Analysts76.67
Price Target8.16 (59.38%)
Short Float %2.71%
Short Ratio4.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.99%
Min EPS beat(2)-161.44%
Max EPS beat(2)-22.55%
EPS beat(4)1
Avg EPS beat(4)197.6%
Min EPS beat(4)-161.44%
Max EPS beat(4)1077.65%
EPS beat(8)3
Avg EPS beat(8)93.15%
EPS beat(12)6
Avg EPS beat(12)93.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.72%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-5.27%
Min Revenue beat(4)-15.17%
Max Revenue beat(4)0.9%
Revenue beat(8)3
Avg Revenue beat(8)-6.42%
Revenue beat(12)6
Avg Revenue beat(12)-3.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.19%
PT rev (3m)-1.23%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)-13.33%
EPS NY rev (3m)15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.85%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.34
P/FCF 61.91
P/OCF 42.74
P/B 1.69
P/tB 1.88
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.08
FCFY1.62%
OCF(TTM)0.12
OCFY2.34%
SpS1.53
BVpS3.02
TBVpS2.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.63%
ROE -4.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.97%
FCFM 5.39%
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.31
Debt/EBITDA N/A
Cap/Depr 69.23%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.33
Quick Ratio 6.38
Altman-Z 5.11
F-Score5
WACC11.31%
ROIC/WACCN/A
Cap/Depr(3y)275.94%
Cap/Depr(5y)279.81%
Cap/Sales(3y)3.98%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1100%
EPS Next Y-241.55%
EPS Next 2Y-42.89%
EPS Next 3Y-10.88%
EPS Next 5YN/A
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%7.29%
Revenue Next Year6.31%
Revenue Next 2Y7.25%
Revenue Next 3Y8.65%
Revenue Next 5YN/A
EBIT growth 1Y-30.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year194.39%
EBIT Next 3Y55.16%
EBIT Next 5YN/A
FCF growth 1Y218.09%
FCF growth 3Y-67.81%
FCF growth 5YN/A
OCF growth 1Y458.05%
OCF growth 3Y-29.64%
OCF growth 5YN/A